Medulloblastoma is one of the most common pediatric brain tumors, accounting for nearly 10 percent of cases. It occurs in the cerebellum, a complex part of the brain that controls balance, coordination and motor function and regulates verbal expression and emotional modulation. While overall survival rates are high, current therapies can be toxic and cause secondary cancers. Developing alternative therapeutics is a priority for the field.
As early as the 1990s, the lab of Scott Pomeroy, MD, PhD, neurologist-in-chief at Boston Children’s Hospital, discovered molecules in medulloblastoma tumors that could predict response to therapies. In 2010, Pomeroy and colleagues uncovered four distinct molecular subtypes of medulloblastoma.
The World Health Organization updated the brain tumor classification scheme in 2016 to include these molecular and genetic features. In the new scheme, tumor subtypes with a good molecular prognosis receive less radiation and chemotherapy. But the creation of targeted therapeutics has remained a challenge, since some of the genetic pathways implicated in these subtypes are found in non-cancerous cells.
Searching for biological significance
A new study, published yesterday in Cancer Cell, turned to proteomics, the large-scale study of proteins in cells. It also looked at the enzymes involved in phosphorylation, the addition of a phosphate group to a molecule and a major mechanism by which proteins are regulated.
Previous tumor typing looked at RNA, which is made from DNA and which the cell “translates” to make proteins. But as the new study showed, there is not necessarily a one-to-one correlation between RNA and the protein it translates.
“We hypothesized that the relationship of protein quantity and its RNA template is not random,” says Pomeroy, a senior author on the paper.
Leveraging proteomics, Pomeroy and colleagues showed that the protein-versus-RNA ratio varies for each medulloblastoma subtype. They also discovered differences in which proteins are actually present from tumor to tumor and how the proteins interact with other molecules in the cell once they’re made.
The results, extending more than 20 years of findings from Pomeroy’s lab, offer a glimpse at potential therapeutic targets in medulloblastoma.
Zeroing in on modified proteins
Pomeroy’s team worked with groups led by Ernest Fraenkel, PhD, professor of biological engineering in MIT’s Department of Biological Engineering, Steven Carr, PhD, senior director of proteomics at the Broad Institute of MIT and Harvard, and Jill Mesirov, PhD, of the Broad Institute and the Moores Cancer Center of UC San Diego to profile 45 medulloblastoma samples. They found extensive “remodeling” of the proteome after translation, even in tumor subtypes with similar patterns of RNA expression.
Since proteins direct biological activities in tumor cells, proteomic and phospho-proteomic analyses are effective ways of identifying potential therapeutic targets.
They discovered that MYC proteins, which are known to drive the growth of cancers, were chemically modified in a subset of the group 3 tumors that had especially poor outcomes. By tracing these protein modifications to their source, the phospho-proteomic analysis pointed to a kinase called PRKDC that plays a role in DNA stability. Inhibiting PRKDC with an existing chemical in these tumor cells sensitized the cells to radiation.
“Although the PRKDC inhibitor has yet to be tested in humans, this could potentially be a viable approach to treating a medulloblastoma subtype with historically poor outcomes,” Pomeroy says.
“Since proteins direct biological activities in tumor cells, global proteomic and phospho-proteomic analyses are effective ways of identifying potential therapeutic targets,” he adds. “We are hopeful that the next phase of our research will bring us even closer to developing viable treatments.”
Related Posts :
Charlee: Bouncing back after neuroblastoma treatment
Call it mother’s intuition, but leading up to her daughter’s cancer diagnosis, Erica Jensen knew something wasn’t ...
Made-to-order therapies get a boost with new FDA guidelines
Science-based treatments for rare genetic diseases have burgeoned in the past decade. That includes diseases so rare they affect just ...
Hip reconstruction in complex patients: Predicting complications
Neuromuscular hip dysplasia and progressive spastic hip displacement are among the most common orthopedic concerns in non-ambulatory children with cerebral ...
Matthew, the ‘wee marvel’: The first gene therapy ALD recipient
When the Elliott brothers are asked how many siblings they have, they always say, “four.” It’s a way of ...